- Home
- BBIO
as 06-20-2025 4:00pm EST
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 7.6B | IPO Year: | 2019 |
| Target Price: | $56.67 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.62 - $41.90 | Next Earning Date: | 07-31-2025 |
| Revenue: | $127,415,000 | Revenue Growth: | -41.71% |
| Revenue Growth (this year): | 102.05% | Revenue Growth (next year): | 54.69% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Valantine Hannah | BBIO | Director | Jun 10 '25 | Sell | $40.00 | 4,292 | $171,680.00 | 1,764 | |
| KKR Genetic Disorder L.P. | BBIO | 10% Owner | May 12 '25 | Sell | $34.20 | 6,000,000 | $205,200,000.00 | 13,260,971 | |
| Lo Andrew | BBIO | Director | May 2 '25 | Sell | $38.50 | 100,000 | $3,849,900.00 | 105,583 | |
| Apuli Maricel | BBIO | Chief Accounting Officer | May 2 '25 | Sell | $38.51 | 1,026 | $39,509.11 | 147,639 | |
| Kumar Neil | BBIO | Chief Executive Officer | Apr 22 '25 | Sell | $34.11 | 75,000 | $2,558,025.00 | 4,873,447 | |
| Ellis Andrea | BBIO | Director | Apr 14 '25 | Sell | $35.00 | 10,000 | $350,000.00 | 12,000 | |
| Ellis Andrea | BBIO | Director | Apr 1 '25 | Sell | $34.05 | 30,000 | $1,021,500.00 | 12,000 | |
| Kumar Neil | BBIO | Chief Executive Officer | Mar 25 '25 | Sell | $36.87 | 75,000 | $2,764,942.50 | 4,873,447 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target
Insider Monkey
9 days ago
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
TipRanks
16 days ago
BridgeBio price target raised to $42 from $37 at BMO Capital
Simply Wall St.
17 days ago
Exploring High Growth Tech Stocks In The US Market
GlobeNewswire
19 days ago
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Barrons.com
a month ago
Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors
Insider Monkey
a month ago
BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment
Zacks
a month ago
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.